Clinical trial
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With Primary IGF-1 Deficiency: A Multi-Center, Open Label, Concentration-Controlled Study
NCT00125190 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With Primary IGF-1 Deficiency: A Multi-Center, Open Label, Concentration-Controlled Study
- Lead sponsor
- Ipsen
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- July 31, 2005
- Completion date
- January 31, 2009
- Enrollment
- 45 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
growth disorders, insulin-like growth factor-1 deficiency